Ruxolitinib: A Review in Polycythaemia Vera

Drugs

Volumn 75, Issue 15, 2015, Pages 1773-1781

  McKeage, Kate ^a  

^a Mairangi Bay   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; RUXOLITINIB; ENZYME INHIBITOR; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; PYRAZOLE DERIVATIVE;

ANEMIA; AREA UNDER THE CURVE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELIMINATION HALF-LIFE; FATIGUE; FOLLOW UP; HEADACHE; HEMATOCRIT; HERPES ZOSTER; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; POLYCYTHEMIA VERA; PRURITUS; REVIEW; SPLEEN SIZE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; TREATMENT OUTCOME;

ENZYME INHIBITORS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; POLYCYTHEMIA VERA; PYRAZOLES; TREATMENT OUTCOME;

EID: 84945491296     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0470-2     Document Type: Review

References (39)

1. Verstovsek S, Komrokji RS. Novel and emerging therapies for the treatment of polycythemia vera. Expert Rev Hematol. 2015;8(1):101-13.
2. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124(24):3529-37.
3. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176-84.
4. Kroll MH, Michaelis LC, Verstovsek S. Mechanisms of thrombogenesis in polycythemia vera. Blood Rev. 2015;29:215-21.
5. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507-13.
6. Tefferi A. CME information: polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management. Am J Hematol. 2015;90:162-73.
7. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126:560-1.
8. Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55:595-600.
9. Passamonti F. How I treat polycythemia vera. Blood. 2012;120(2):275-84.
10. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761-70.
11. Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119:1363-9.
12. Quintás-Cardama A, Verstovsek S. Molecular pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19(8):1933-40.
13. Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015;75(3):297-308.
14. Yang LP, Keating GM. Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012;72(16):2117-27.
15. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-17.
16. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513-20.
17. European Medicines Agency. Jakavi (ruxolitinib): summary of product characteristics. 2015. http://ec.europa.eu. Accessed 2 July 2015.
18. Incyte. Jakafi (ruxolitinib) tablets: US prescribing information. 2014. http://www.jakafi.com. Accessed 3 July 2015.
19. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51:1644-54.
20. 14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010;38:2023-31.
21. Chen X, Williams WV, Sandor V, et al. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol. 2013;53(7):721-30.
22. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-35.
23. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829-33.
24. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961-3.
25. Passamonti F, Harrison CN, Pane F, et al. Ruxolitinib vs best available therapy in patients with polycythemia vera treated in the RESPONSE study: a subgroup analysis of hydroxyurea- and non-hydroxyurea-treated patients [abstract]. In: European Hematology Association 20th Congress. 2015.
26. Verstovsek S, Harrison C, Kiladjian JJ, et al. Effect of ruxolitinib on markers of iron deficiency: an analysis of the RESPONSE trial [abstract]. In: European Hematology Association 20th Congress. 2015.
27. Verstovsek S, Kiladjian JJ, Mesa R, et al. Ruxolitinib efficacy by hematocrit control in patients with polycythemia vera: an analysis of the RESPONSE trial [abstract no. 3201]. Blood. 2014;124:3201.
28. Kiladjian JJ, Vannucchi AM, Griesshammer M, et al. Clinical benefit of ruxolitinib treatment after crossover from best available therapy in patients with polycythemia vera: analysis of the RESPONSE trial [abstract no. 3181]. Blood. 2014;124:3181.
29. Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib in polycythemia vera: follow-up from the RESPONSE trial [abstract no. 7087]. J Clin Oncol. 2015;33(15 Suppl).
30. Griesshammer M, Passamonti F, Durrant S, et al. Ruxolitinib provides consistent hematocrit control in patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea [abstract]. In: European Hematology Association 20th Congress. 2015.
31. Harrison C, Masszi T, Zachee P, et al. Complete hematologic control with ruxolitinib in patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea [abstract]. In: European Hematology Association 20th Congress. 2015.
32. Verstovsek S, Mesa R, Martino B, et al. Safety of ruxolitinib in patients with polycythemia vera: results from the clinical trial program [abstract]. In: European Hematology Association 20th Congress. 2015.
33. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-61.
34. Kiladjian JJ, Winton EF, Talpaz M, et al. Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol. 2015;8:391-401.
35. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874-81.
36. Leukemia and Hematosarcoma Cooperative Group, European Organization for Research on Treatment of Cancer (EORTC). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer. 1981;44:75-80.
37. Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol. 2014;93:2037-43.
38. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047-53.
39. Mascarenhas JO, Cross NCP, Mesa RA. The future of JAK inhibition in myelofibrosis and beyond. Blood Rev. 2014;28(5):189-96.